Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 14/20 | 1.00 |
| ▸ | BRD1 | O95696 | 8/20 | 0.57 |
| ▸ | BRD4 | O60885 | 8/20 | 0.57 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.57 |
| ▸ | BRPF3 | Q9ULD4 | 4/20 | 0.57 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17560677 | 0.94 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560692 | 0.83 | BRPF1 (0.71) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560668 | 0.78 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL17560655 | 0.76 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL20782358 | 0.75 | BRPF1 (0.60) | BRPF1BRD4TRIM24SYK | |
| SCHEMBL17560702 | 0.75 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL20775376 | 0.73 | BRPF1 (0.58) | BRPF1BRD4SYK | |
| SCHEMBL19435605 | 0.73 | BRPF1 (1.00) | BRPF1BRD1BRD4BRD9BRPF3 | |
| SCHEMBL28614349 | 0.72 | BRPF1 (0.56) | BRPF1BRD4 | |
| SCHEMBL17560722 | 0.72 | BRPF1 (0.79) | BRPF1BRD1BRD4BRD9BRPF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | claimed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3189037-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL Business PLC (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | BRPF1 104/4885BRD1 4/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.